Completed PHASE3 INTERVENTIONAL NCT00273247

Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis

Adjuvant α-Interferon Treatment After Resection of Hepatocellular Carcinoma in HCV-Related Cirrhosis: a Randomized Trial on Prevention of Cancer Recurrence

Sponsor: Associazione Italiana per la Ricerca sul Cancro

Conditions Hepatic Resection Hepatitis C Virus Infection Hepatocellular Carcinoma Interferon Treatment Liver Cirrhosis

Interventions Interferon alpha-2b

Updated 4 times since 2017 Last updated: Jan 5, 2006 Started: Jun 30, 1998 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hepatic Resection and Hepatitis C Virus Infection, this trial is completed. The trial is conducted by Associazione Italiana per la Ricerca sul Cancro and has accumulated 4 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Jun 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Associazione Italiana per la Ricerca sul Cancro
National Cancer Institute, Milan

Data source: National Cancer Institute, Milan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy